ECS Botanics general manager of production and research and development, Jesus Diaz, has joined Austranna as cultivation director.

Diaz joined ECS from Little Green Pharma in July 2023, initially as technical manager before taking the GM role in October the same year.
Announcing the move on LinkedIn, Diaz said he was excited about the “challenges and opportunities” at Austranna.
His previous roles include a near three-year spell at Tasmanian Botanics.
Emyria
Dr Michael Winlo has stepped down as managing director and chief executive of Emyria and taken the role of chief scientific officer. He will oversee the firm’s real-world evidence research, clinical trials and proprietary drug-development programs.

Dr Winlo will report into Greg Hutchinson who has been named executive chairman, having previously held the role on a non-executive basis.
“Emyria is uniquely positioned to transform mental health care in Australia as well as other global jurisdictions,” Hutchinson said. “I look forward to positioning the company for growth and driving expansion of its exceptional clinical services to meet the rising demand for better health interventions.
“I would like to thank Dr Winlo for his five years of service as MD and CEO of Emyria.”
Dr Winlo predicted 2025 will be a “transformative year” for the company.